Idera: Idera climbs on Phase II readout for tilsotolimod in melanoma
Based on the results, the company said the INTRIM 1 trial evaluating its synthetic Toll-like receptor 9 agonist has been stopped early.
Read full article »
Idera is an infrastructure software firm that provides testing, application development and database management solutions for businesses.
Read more